Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)
CNY 44.61
(0.29%)
CNY 44.61
(0.29%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.38 Billion CNY | 3.82% |
| 2022 | 7.08 Billion CNY | 35.91% |
| 2021 | 5.21 Billion CNY | 63.32% |
| 2020 | 3.19 Billion CNY | 13.88% |
| 2019 | 2.8 Billion CNY | 21.85% |
| 2018 | 2.3 Billion CNY | 36.37% |
| 2017 | 1.68 Billion CNY | 43.63% |
| 2016 | 1.17 Billion CNY | 22.73% |
| 2015 | 956.99 Million CNY | 53.23% |
| 2014 | 624.56 Million CNY | 85.59% |
| 2013 | 336.51 Million CNY | 32.32% |
| 2012 | 254.31 Million CNY | 31.59% |
| 2011 | 193.26 Million CNY | 57.32% |
| 2010 | 122.84 Million CNY | 95.63% |
| 2009 | 62.79 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 1.7 Billion CNY | 1.07% |
| 2024 Q1 | 1.65 Billion CNY | -4.32% |
| 2024 Q2 | 1.69 Billion CNY | 2.34% |
| 2023 Q4 | 1.72 Billion CNY | -10.96% |
| 2023 FY | 7.35 Billion CNY | 3.82% |
| 2023 Q1 | 1.8 Billion CNY | 7.45% |
| 2023 Q2 | 1.9 Billion CNY | 5.64% |
| 2023 Q3 | 1.93 Billion CNY | 1.75% |
| 2022 Q2 | 1.77 Billion CNY | -2.28% |
| 2022 FY | 7.08 Billion CNY | 35.91% |
| 2022 Q4 | 1.67 Billion CNY | -7.31% |
| 2022 Q3 | 1.81 Billion CNY | 2.0% |
| 2022 Q1 | 1.81 Billion CNY | -0.04% |
| 2021 Q2 | 1.15 Billion CNY | 27.99% |
| 2021 Q1 | 901.94 Million CNY | 1.14% |
| 2021 Q3 | 1.33 Billion CNY | 15.96% |
| 2021 Q4 | 1.81 Billion CNY | 35.85% |
| 2021 FY | 5.21 Billion CNY | 63.32% |
| 2020 Q1 | 650.1 Million CNY | -15.82% |
| 2020 Q3 | 848.47 Million CNY | 5.81% |
| 2020 FY | 3.19 Billion CNY | 13.88% |
| 2020 Q4 | 891.81 Million CNY | 5.11% |
| 2020 Q2 | 801.88 Million CNY | 23.35% |
| 2019 Q4 | 772.31 Million CNY | 11.33% |
| 2019 FY | 2.8 Billion CNY | 21.85% |
| 2019 Q3 | 693.7 Million CNY | -4.76% |
| 2019 Q2 | 728.4 Million CNY | 19.63% |
| 2019 Q1 | 608.88 Million CNY | -13.78% |
| 2018 Q1 | 473.15 Million CNY | -7.6% |
| 2018 Q4 | 706.21 Million CNY | 25.73% |
| 2018 FY | 2.3 Billion CNY | 36.37% |
| 2018 Q3 | 561.67 Million CNY | 0.37% |
| 2018 Q2 | 559.61 Million CNY | 18.27% |
| 2017 Q3 | 431.75 Million CNY | 11.32% |
| 2017 Q4 | 512.08 Million CNY | 18.61% |
| 2017 FY | 1.68 Billion CNY | 43.63% |
| 2017 Q1 | 355.33 Million CNY | 9.3% |
| 2017 Q2 | 387.86 Million CNY | 9.15% |
| 2016 Q2 | 291.27 Million CNY | 6.11% |
| 2016 Q3 | 283.67 Million CNY | -2.61% |
| 2016 FY | 1.17 Billion CNY | 22.73% |
| 2016 Q4 | 325.09 Million CNY | 14.6% |
| 2016 Q1 | 274.49 Million CNY | -8.64% |
| 2015 Q4 | 300.44 Million CNY | 30.92% |
| 2015 Q2 | 210.76 Million CNY | -2.56% |
| 2015 Q1 | 216.3 Million CNY | 5.17% |
| 2015 FY | 956.99 Million CNY | 53.23% |
| 2015 Q3 | 229.49 Million CNY | 8.89% |
| 2014 Q4 | 205.66 Million CNY | 9.41% |
| 2014 Q3 | 187.98 Million CNY | 63.08% |
| 2014 Q2 | 115.26 Million CNY | -0.33% |
| 2014 FY | 624.56 Million CNY | 85.59% |
| 2014 Q1 | 115.64 Million CNY | 27.52% |
| 2013 Q2 | 91.35 Million CNY | 21.85% |
| 2013 FY | 336.51 Million CNY | 32.32% |
| 2013 Q4 | 90.69 Million CNY | 14.09% |
| 2013 Q3 | 79.49 Million CNY | -12.98% |
| 2013 Q1 | 74.97 Million CNY | 9.41% |
| 2012 Q2 | 65.64 Million CNY | 16.39% |
| 2012 FY | 254.31 Million CNY | 31.59% |
| 2012 Q4 | 68.52 Million CNY | 7.51% |
| 2012 Q3 | 63.74 Million CNY | -2.9% |
| 2012 Q1 | 56.4 Million CNY | 10.61% |
| 2011 Q3 | 48.7 Million CNY | 0.0% |
| 2011 FY | 193.26 Million CNY | 57.32% |
| 2011 Q4 | 50.99 Million CNY | 4.69% |
| 2010 FY | 122.84 Million CNY | 95.63% |
| 2009 FY | 62.79 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 13.4 Billion CNY | 44.929% |
| Dirui Industrial Co.,Ltd. | 1.36 Billion CNY | -441.622% |
| Beijing Strong Biotechnologies, Inc. | 1.74 Billion CNY | -323.974% |
| Medicalsystem Biotechnology Co., Ltd. | 1.88 Billion CNY | -291.546% |
| Maccura Biotechnology Co.Ltd | 2.89 Billion CNY | -154.994% |
| Guangzhou Wondfo Biotech Co.,Ltd | 2.76 Billion CNY | -167.062% |
| Guangdong Hybribio Biotech Co.,Ltd. | 1.1 Billion CNY | -568.569% |
| BGI Genomics Co., Ltd. | 4.34 Billion CNY | -69.762% |
| Amoy Diagnostics Co., Ltd. | 1.03 Billion CNY | -610.8% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1.67 Billion CNY | -341.004% |